Celgene Corp. forecast 2018 total revenue that fell short of analysts’ estimates, sending the company’s shares down 3 percent.
Amgen Inc. said the U.S. FDA approved its drug Xgeva to prevent fractures in patients with multiple myeloma.
Janssen Biotech Inc. entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen.
Sanofi management expressed confidence that the company’s pipeline of new products will support long-term growth.
Six months after losing its CEO, Galena Biopharma was absorbed in a reverse merger with Sellas Life Sciences to form a new company, Sellas Life Science Group Inc. The newly merged companies will focus on developing novel treatments for cancer.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a variation to the marketing application to the European Medicines Agency to include overall survival data from the Phase 3 head-to-head ENDEAVOR trial in the product information for Kyprolis (carfilzomib).
Although a lot of attention went to unexpected data by China’s Nanjing Legend Biotech, bluebird bio and Celgene had CAR-T data of their own to brag about.
Janssen-Cilag International NV announced that the European Commission granted approval to Darzalex (daratumumab) for use in combination with lenalidomide and dexamethasone, or bortezomib – which is marketed as Velcade – and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Patients with relapsed multiple myeloma treated with Amgen Inc.’s Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co.’s Velcade, according to data from a late-stage study released by Amgen.